Falcon Point Capital’s Celgene Corp CELG Stock Holding History

Falcon Point Capital’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-12,510	Closed	-$1.06M	–	137
2013 Q4	$1.06M	Sell	12,510 -1,060	-8%	-$83.9K	1.01%	29
2013 Q3	$1.05M	Sell	13,570 -1,006	-7%	-$70.5K	1.12%	23
2013 Q2	$853K	Buy	+14,576	New	+$877K	0.94%	36

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Falcon Point Capital's CELG Position: Q1 2014 in Review

Falcon Point Capital sold out of Celgene Corp (CELG) in Q1 2014, closing a stake of 12,510 shares — an estimated $1.06M sold.

Falcon Point Capital first reported a position in CELG in Q2 2013 and held it in 3 quarters. The position peaked at $1.06M in Q4 2013. 980 funds tracked by Wall St. Rank hold CELG as of Q1 2014.

Falcon Point Capital reported no remaining Celgene Corp position as of Q1 2014 after selling out during the quarter.
Falcon Point Capital sold 12,510 Celgene Corp shares in Q1 2014, an estimated $1.06M.
Falcon Point Capital first reported a position in Celgene Corp in Q2 2013 and held it in 3 quarters.
Falcon Point Capital's Celgene Corp position peaked at $1.06M in Q4 2013.
980 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2014.

Based on Falcon Point Capital's 13F filing for Q1 2014, filed 28 Apr 2014.